Moderna (MRNA) Long-Term Deferred Tax (2021 - 2024)

Moderna (MRNA) has reported Long-Term Deferred Tax for 4 consecutive years, with $81.0 million the latest figure, recorded in Q3 2024.

• On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $81.0 million in Q3 2024; TTM through Sep 2024 was $81.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $81.0 million, down 91.75% from the prior year.
• Long-Term Deferred Tax was $81.0 million for Q3 2024 at Moderna, roughly flat from $81.0 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $1.5 billion in Q2 2023 and troughed at $50.0 million in Q1 2021.
• A 4-year average of $485.5 million and a median of $203.5 million in 2021 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 1089.39% in 2022 and slumped 94.53% in 2024, its largest moves.
• Over 4 years, Long-Term Deferred Tax stood at $326.0 million in 2021, then soared by 201.23% to $982.0 million in 2022, then slumped by 91.75% to $81.0 million in 2023, then changed by 0.0% to $81.0 million in 2024.
• The last three Long-Term Deferred Tax figures came in at $81.0 million (Q3 2024), $81.0 million (Q2 2024), and $81.0 million (Q1 2024), per Business Quant data.